No headlines found.
Anbio Biotechnology Announces Closing of Initial Public Offering
Globe Newswire (Thu, 20-Feb 9:50 AM ET)
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. Its research and development activities for all IVD products: Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer. Its product AF-1200 Fluorescence Immunoassay Analyzer, AF-100 Fluorescence Immunoassay Analyzer, AF-100S Fluorescence Immunoassay Analyzer, AF-100C Fluorescence Immunoassay Analyzer.
Anbio Biotechnology - Class A trades on the NASDAQ stock market under the symbol NNNN.
As of March 10, 2025, NNNN stock price declined to $6.21 with 188,089 million shares trading.
NNNN has a market cap of $272.56 million. This is considered a Small Cap stock.
NNNN support price is $6.50 and resistance is $7.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NNNN shares will trade within this expected range on the day.